Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Channing J Der

Showing results (221-230 of 236) with videos related to

Pageof 24
Sort By:
Cell Reports|December 1, 2021
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatmentJennifer E Klomp, Ye S Lee, Craig M Goodwin, et al.
Cancer Discovery|October 26, 2019
Atypical KRAS<sup>G12R</sup> Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic CancerG Aaron Hobbs, Nicole M Baker, Anne M Miermont, et al.
Nature Medicine|June 3, 2020
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Nature Medicine|March 6, 2019
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Science (New York, N.Y.)|June 6, 2024
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancersJeffrey A Klomp, Jennifer E Klomp, Clint A Stalnecker, et al.
Cell Reports|June 17, 2026
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibitionAndrew M Waters, Tala O Khatib, Bjoern Papke, et al.
Cell Reports|June 30, 2021
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibitionAndrew M Waters, Tala O Khatib, Bjoern Papke, et al.
JCO Precision Oncology|September 2, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic CancerRishi Surana, Micaela Morgado, Ashwin Somasundaram, et al.
Science Translational Medicine|September 3, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancerKathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, et al.
Cancer Cell|June 20, 2020
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic CancerLuisa F Escobar-Hoyos, Alex Penson, Ram Kannan, et al.
Pageof 24

Showing results (221-230 of 236) with videos related to

Sort By:
Pageof 24
Cell Reports|December 1, 2021
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatmentJennifer E Klomp, Ye S Lee, Craig M Goodwin, et al.
Cancer Discovery|October 26, 2019
Atypical KRAS<sup>G12R</sup> Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic CancerG Aaron Hobbs, Nicole M Baker, Anne M Miermont, et al.
Nature Medicine|June 3, 2020
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Nature Medicine|March 6, 2019
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancerKirsten L Bryant, Clint A Stalnecker, Daniel Zeitouni, et al.
Science (New York, N.Y.)|June 6, 2024
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancersJeffrey A Klomp, Jennifer E Klomp, Clint A Stalnecker, et al.
Cell Reports|June 17, 2026
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibitionAndrew M Waters, Tala O Khatib, Bjoern Papke, et al.
Cell Reports|June 30, 2021
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibitionAndrew M Waters, Tala O Khatib, Bjoern Papke, et al.
JCO Precision Oncology|September 2, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic CancerRishi Surana, Micaela Morgado, Ashwin Somasundaram, et al.
Science Translational Medicine|September 3, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancerKathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, et al.
Cancer Cell|June 20, 2020
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic CancerLuisa F Escobar-Hoyos, Alex Penson, Ram Kannan, et al.
Pageof 24